Recombinant Human Pyruvate kinase PKLR (PKLR), Homo sapiens (Human), E.coli, N-terminal 6xHis-tagged, 65.8kDa, purity >90% as determined by SDS-PAGE.
, ,

Recombinant Human Pyruvate kinase PKLR (PKLR)

Recombinant Human Pyruvate kinase PKLR (PKLR) — Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis. Purity >90%.

SKU: BCRECP-001389 Categories: , ,
Online Inquiry →

Product Specifications

Product SkuBCRECP-001389
Product DescriptionRecombinant Human Pyruvate kinase PKLR (PKLR) Protein is expressed from E.coli with N-terminal 6xHis-tagged. It contains 1-574aa. [Accession | P30613].
Uniprot No.P30613
Gene NamesPKLR
PurityGreater than 90% as determined by SDS-PAGE.
Expression SystemE.coli
Expression Region1-574aa
SpeciesHomo sapiens (Human)
Tag InfoN-terminal 6xHis-tagged
Molecular weight65.8kDa
ActivityPlease contact us to obtain bioactivity data.
BufferIf the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose.
StorageStore at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Research AreasMetabolism

Function

Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis. Also produces the side product 2-phospholactate which can inhibit fructose-2,6-bisphosphate production. 2-phospholactate can be dephosphorylated by PGP which prevents the inhibition of fructose-2,6-bisphosphate production and allows glycolysis to occur.

Biological Context

Disease Association: Pyruvate kinase hyperactivity (PKHYP) : Autosomal dominant phenotype characterized by increase of red blood cell ATP. [The disease is caused by variants affecting the gene represented in this entry] | Anemia, congenital, non-spherocytic hemolytic, 2 (CNSHA2) : An autosomal recessive disorder characterized by a variable degree of chronic hemolysis and decreased red cell pyruvate kinase activity. Clinical manifestations range from fatal anemia at birth to a fully compensated hemolysis without apparent anemia. [The disease is caused by variants affecting the gene represented in this entry]
Pathway: Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5

Product Specifications

Recombinant Human Pyruvate kinase PKLR (PKLR) is a recombinant protein from Homo sapiens (Human), expressed in E.coli, covering amino acids 1-574aa, with N-terminal 6xHis-tagged tag, molecular weight 65.8kDa, purity Greater than 90% as determined by SDS-PAGE.. Suitable for ELISA and Western Blot applications.

Recommended applications depend on the target, product format, and product-specific validation data. Refer to the product datasheet or Certificate of Analysis (CoA), or contact BioCrest Sci for application guidance.

Biological Activity: Please contact us to obtain bioactivity data.

Storage: Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.

Shipping & Lead Time: Availability, shipping conditions, and estimated lead time are confirmed in the formal quotation or order confirmation based on the product format, destination, and order requirements.

Related products

Protein Biology

Function

Pyruvate kinase that catalyzes the conversion of phosphoenolpyruvate to pyruvate with the synthesis of ATP, and which plays a key role in glycolysis (PubMed:11960989). Also produces the side product 2-phospholactate which can inhibit fructose-2,6-bisphosphate production (PubMed:27294321). 2-phospholactate can be dephosphorylated by PGP which prevents the inhibition of fructose-2,6-bisphosphate production and allows glycolysis to occur (PubMed:27294321)

Disease Association

Pyruvate kinase hyperactivity (PKHYP) : Autosomal dominant phenotype characterized by increase of red blood cell ATP. [The disease is caused by variants affecting the gene represented in this entry] | Anemia, congenital, non-spherocytic hemolytic, 2 (CNSHA2) : An autosomal recessive disorder characterized by a variable degree of chronic hemolysis and decreased red cell pyruvate kinase activity. Clinical manifestations range from fatal anemia at birth to a fully compensated hemolysis without apparent anemia. [The disease is caused by variants affecting the gene represented in this entry]

Subunit

Homotetramer

Pathway

Carbohydrate degradation; glycolysis; pyruvate from D-glyceraldehyde 3-phosphate: step 5/5

Gene: PKLR  |  Organism: Homo sapiens  |  Synonyms: Pyruvate kinase 1; Pyruvate kinase isozymes L/R; R-type/L-type pyruvate kinase; Red cell/liver pyruvate kinase
Key Publications

Explore closely related product collections, technology platforms, and custom production resources.

Frequently Asked Questions

How do I order or inquire about this product?

Submit the Online Inquiry form with your required quantity and specifications, or email sales@biocrestsci.com. Available sizes, pricing, stock status, documentation, and estimated lead time are confirmed in the formal quotation.

What is the shipping and delivery time?

Availability, dispatch timing, shipping conditions, and delivery estimates depend on the product format, destination, and order requirements. These details are confirmed in the formal quotation or order confirmation.

How should this product be stored?

Follow the storage and handling instructions in the product-specific datasheet and Certificate of Analysis (CoA). Requirements may vary by product form and formulation; contact BioCrest Sci if product-specific guidance is needed.

What quality controls are performed on your products?

Quality-control data such as identity, purity, endotoxin level, or biological activity are provided only when specified on this product page, the datasheet, or Certificate of Analysis (CoA). Biological activity is not implied unless explicitly stated.

Shopping Cart
Scroll to Top